Tomasz Stryjewski, MD
Ophthalmology · Boston, MANPI 1164860151
Payments from drug & device makers
Across 39 payments — averaging $250.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$4K
- Novartis$1K
- Alimera Sciences, Inc.$1K
- Regeneron$1K
- Alcon$800
- Samsara Vision$263
- plus $686 from 11 others
What the payments were for
- Consulting fees$5,46356%
- Speaking & faculty fees$1,20012%
- Travel & lodging$1,03511%
- Food & beverage$2,06221%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1 | $4,410 |
| Novartis | 3 | $1,351 |
| Alimera Sciences, Inc. | 3 | $1,230 |
| Regeneron | 4 | $1,037 |
| Alcon | 8 | $800 |
| Samsara Vision | 5 | $263 |
| Carl Zeiss Meditec, Inc. | 1 | $168 |
| Beaver-visitec International, Inc. | 1 | $144 |
| Astellas Pharma US Inc | 1 | $120 |
| AbbVie | 2 | $51 |
| Apellis Pharmaceuticals, Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Genentech USA, Inc. | 1 | $29 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Eyepoint US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$1,281
- Iluvien$1,200
- Constellation$559
- VERACITY SURGICAL$168
- Implantable Miniature Telescope$145
- EYLEA$107
How this compares
$9,777 in reported general payments places this provider in the 80th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 174 | $9,331 |
| Ketorolac Tromethamine | 127 | $3,641 |
| Ofloxacin | 118 | $1,976 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 14 | $958 |
| Latanoprost | 54 | $706 |
| Brimonidine Tartrate | 51 | $671 |
| Timolol Maleate | 14 | $604 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $130 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Jennifer SunBoston$4.2M
- Lloyd AielloBoston$3.1M
- Rishi SinghBoston$2.5M
- Jack GreinerBoston$523K
- Reza DanaBoston$510K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- David FriedmanBoston$259K
- Dean EliottBoston$250K
- Michael RaizmanBoston$237K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.